buy kamagra online in australia viagra shipped to australia viagra western australia
where can i buy flagyl 500 mg medicament prednisolone biogaran 20 mg where can i buy deltasone
comprare viagra senza ricetta viagra kaufen per nachnahme acquistare cialis su internet
ventolin hfa price usa 
can diflucan be purchased without a prescription 
propecia cheapest online 
lansoprazole vente clomid acheter clomiphene sur le comptoir
doxycycline incontinence dog topamax mexican pharmacy doxycycline lyme
buy microsoft office outlook download purchase efex pro 3 download cost of photoshop lightroom
autocad mechanical 2015 download buying photoshop cs3 for mac price of office 2011

Cancer Prevention Research

Mon, Nov 25, 2013

Oral Cancer News

 

Clinical and biochemical studies support smokeless tobacco’s carcinogenic potential in the human oral cavity

 
Source: American Association of Cancer Research
Published: November 9, 2013
By: Susan R. Mallery, Meng Tong, Gregory C. Michaels, Amber R. Kiyani, and Stephen S. Hecht

 

Abstract

In 2007, International Agency for Cancer Research presented compelling evidence that linked smokeless tobacco use to the development of human oral cancer. While these findings imply vigorous local carcinogen metabolism, little is known regarding levels and distribution of Phase I, II and drug egress enzymes in human oral mucosa. In the study presented here, we integrated clinical data, imaging and histopathologic analyses of an oral squamous cell carcinoma that arose at the site of smokeless tobacco quid placement in a patient. Immunoblot and immunohistochemical (IHC) analyses were employed to identify tumor and normal human oral mucosal smokeless tobacco-associated metabolic activation and detoxification enzymes. Human oral epithelium contains every known Phase I enzyme associated with nitrosamine oxidative bioactivation with ~2 fold inter-donor differences in protein levels. Previous studies have confirmed ~3.5 fold inter-donor variations in intraepithelial Phase II enzymes. Unlike the superficially located enzymes in non-replicating esophageal surface epithelium, IHC studies confirmed oral mucosal nitrosamine metabolizing enzymes reside in the basilar and suprabasilar region which notably is the site of ongoing keratinocyte DNA replication. Clearly, variations in product composition, nitrosamine metabolism and exposure duration will modulate clinical outcomes. The data presented here form a coherent picture consistent with the abundant experimental data that links tobacco-specific nitrosamines to human oral cancer.

 

* This news story was resourced by the Oral Cancer Foundation, and vetted for appropriateness and accuracy.

 

Print Friendly
Be Sociable, Share!
, , ,

Leave a Reply

You must be logged in to post a comment.